Coloplast A/S (OTCMKTS:CLPBY) Rating Increased to Strong-Buy at Sanford C. Bernstein

Sanford C. Bernstein upgraded shares of Coloplast A/S (OTCMKTS:CLPBY) from a hold rating to a strong-buy rating in a research report released on Tuesday,Zacks.com reports.

CLPBY has been the subject of a number of other research reports. UBS Group upgraded Coloplast A/S from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 11th. Hsbc Global Res upgraded shares of Coloplast A/S from a “moderate sell” rating to a “hold” rating in a research note on Monday, November 18th.

Coloplast A/S Stock Performance

CLPBY opened at $11.59 on Tuesday. Coloplast A/S has a 12-month low of $10.63 and a 12-month high of $14.34. The stock’s 50 day moving average price is $11.54 and its two-hundred day moving average price is $12.61. The company has a quick ratio of 0.66, a current ratio of 1.02 and a debt-to-equity ratio of 0.92.

Coloplast A/S (OTCMKTS:CLPBY) last announced its earnings results on Tuesday, November 5th. The company reported $0.08 earnings per share (EPS) for the quarter. The business had revenue of $1.02 billion for the quarter. Coloplast A/S had a net margin of 18.69% and a return on equity of 30.19%. Sell-side analysts predict that Coloplast A/S will post 0.36 earnings per share for the current year.

Coloplast A/S Increases Dividend

The firm also recently announced a dividend, which was paid on Friday, December 20th. Shareholders of record on Monday, December 9th were given a dividend of $0.2435 per share. The ex-dividend date was Monday, December 9th. This is an increase from Coloplast A/S’s previous dividend of $0.05. Coloplast A/S’s dividend payout ratio is presently 90.91%.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.